ENTITY
BeiGene

BeiGene (6160 HK)

303
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
29 Dec 2021 09:07

Lifetech Scientific (1302.HK) - A “dark Horse” in China Innovative Device Industry

This insight analyzed Lifetech in terms of its three main product lines, the growth points and the outlook in the future, short-term catalysts and...

Logo
400 Views
Share
27 Dec 2021 09:13

China Healthcare Weekly (Dec.24)- Capital Arbitrage, Drug Commercial Results, Healthcare Big Picture

This insight analyzed the concerns on capital arbitrage in domestic innovative drugs, the unsatisfactory innovative drug commercial results,...

Logo
349 Views
Share
bullishZai Lab Ltd
21 Dec 2021 09:07

Zai Lab Ltd (ZLAB.US) - The Strength and the Concerns

This insight analyzes Zai Lab about its distinctive pipeline, the management team, the concerns on license-in mode, regulatory...

Logo
268 Views
Share
19 Dec 2021 09:07

China Healthcare Weekly (Dec.17)-The Most Important Policy in Next Three Years,Pacemaker VBP Results

This article analyzed the most important policy for China healthcare in the next three years - DRGs/DIP, its potential impact, the outlook of...

Logo
345 Views
Share
bearishWuxi Biologics
16 Dec 2021 08:15

Potential Blacklist Additions: Impact on China AI/Biotech Stocks

An FT article said that the Biden administration would add 8 entities to the NS-CMIC list and 24 entities to the Entity List. We look at the...

Logo
483 Views
Share
x